Impact of Paroxysmal Atrial Tachycardia on Thromboembolic Events and Major Adverse Cardiovascular Events: A Single-Center Retrospective Study

Overview

Journal Risk Manag Healthc Policy

Publisher Dove Medical Press

Specialty Public Health

Date 2024 Nov 4

PMID 39493378

Authors

Peng Liu

Tingting Lv

Yuanwei Liu

Xiaofei Zhang

Fei She

Rong He

Dan Li

Lianfeng Liu

Ping Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Atrial fibrillation (AF) is known to increase the risk of thromboembolic events and major adverse cardiovascular events (MACE). The impact of paroxysmal atrial tachycardia (PAT) on these risks remains unclear.

Methods: This retrospective cohort study was conducted involving 889 patients diagnosed with PAT and 1106 control patients without PAT, all of whom underwent their initial 24-hour ECG monitoring between 2015 to 2020. Kaplan-Meier survival analysis and Cox regression analysis were used to evaluate the association between PAT and the study endpoints, including thromboembolic events and MACE.

Results: Over a mean follow-up period of 50.3 months, the incidence of thromboembolic events and MACE was significantly higher in the PAT group compared to the control group (6.5% vs 1.7% and 19.1% vs 9.9%, respectively). After adjusting for common risk factors and baseline imbalances, the PAT group exhibited a significantly elevated risk of thromboembolic events (hazard ratio [HR] 3.782, 95% confidence interval [CI] 2.212-6.467; <0.001) and MACE (HR 1.795, 95% CI 1.398-2.305; <0.001). However, the frequency of PAT episodes, heart rate, and maximum heart rate were not significantly associated with these outcomes. Within the PAT group, a history of stroke, transient ischemic attack, and chronic renal failure were identified as independent risk factors for thromboembolic events, while hypertension, coronary heart disease, heart failure, and chronic renal failure were independently associated with MACE.

Conclusion: PAT, as detected by 24-hour dynamic ECG, is associated with an increased risk of thromboembolic events and MACE.

References

Binici Z, Intzilakis T, Nielsen O, Kober L, Sajadieh A . Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010; 121(17):1904-11. DOI: 10.1161/CIRCULATIONAHA.109.874982. View

Inohara T, Kohsaka S, Okamura T, Watanabe M, Nakamura Y, Higashiyama A . Long-term outcome of healthy participants with atrial premature complex: a 15-year follow-up of the NIPPON DATA 90 cohort. PLoS One. 2013; 8(11):e80853. PMC: 3834303. DOI: 10.1371/journal.pone.0080853. View

Chong B, Pong V, Lam K, Liu S, Zuo M, Lau Y . Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace. 2011; 14(7):942-7. DOI: 10.1093/europace/eur389. View

Polovina M, dikic D, Vlajkovic A, Vilotijevic M, Milinkovic I, Asanin M . Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. Int J Cardiol. 2017; 249:191-197. DOI: 10.1016/j.ijcard.2017.09.154. View

de Souza Lima Bitar Y, Gomes Neto M, Lima Filho J, Pereira L, Travassos K, Akrami K . Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. Drugs R D. 2019; 19(2):117-126. PMC: 6544604. DOI: 10.1007/s40268-019-0274-z. View

Vitolo M, Imberti J, Maisano A, Albini A, Bonini N, Valenti A . Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Intern Med. 2021; 92:100-106. DOI: 10.1016/j.ejim.2021.05.038. View

Denas G, Santostasi G, Pengo V . The safety of available pharmacotherapy for stroke prevention in atrial fibrillation. Expert Opin Drug Saf. 2024; 23(11):1371-1380. DOI: 10.1080/14740338.2024.2409698. View

Dewland T, Vittinghoff E, Mandyam M, Heckbert S, Siscovick D, Stein P . Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013; 159(11):721-8. PMC: 4115459. DOI: 10.7326/0003-4819-159-11-201312030-00004. View

Yang Y, Shao X, Zhu J, Zhang H, Liu Y, Gao X . Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: a national wide database analysis. Int J Cardiol. 2014; 173(2):242-7. DOI: 10.1016/j.ijcard.2014.02.040. View

10.

Stern E, Georgiou D, Schweitzer P . Relation between nonsustained atrial tachycardia and paroxysmal atrial fibrillation. Am J Cardiol. 1986; 57(4):339-40. DOI: 10.1016/0002-9149(86)90916-1. View

11.

Sharma S, Kondur A, Gopinathannair R, Kamerzell T, Mansour M, Mahapatra S . Is paroxysmal supraventricular tachycardia truly benign? Insightful association between PSVT and stroke from a National Inpatient Database Study. J Interv Card Electrophysiol. 2019; 59(1):35-41. DOI: 10.1007/s10840-019-00651-7. View

12.

Engstrom G, Hedblad B, Juul-Moller S, Tyden P, Janzon L . Cardiac arrhythmias and stroke: increased risk in men with high frequency of atrial ectopic beats. Stroke. 2000; 31(12):2925-9. DOI: 10.1161/01.str.31.12.2925. View

13.

Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013; 383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0. View

14.

Wolf P, Kannel W, McGee D, Meeks S, Bharucha N, MCNAMARA P . Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke. 1983; 14(5):664-7. DOI: 10.1161/01.str.14.5.664. View

15.

Johnson L, Juhlin T, Juul-Moller S, Hedblad B, Nilsson P, Engstrom G . A prospective study of supraventricular activity and incidence of atrial fibrillation. Heart Rhythm. 2015; 12(9):1898-904. DOI: 10.1016/j.hrthm.2015.04.042. View

16.

Kirchhof P, Toennis T, Goette A, Camm A, Diener H, Becher N . Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med. 2023; 389(13):1167-1179. DOI: 10.1056/NEJMoa2303062. View

17.

Rujirachun P, Wattanachayakul P, Winijkul A, Ungprasert P . Paroxysmal supraventricular tachycardia and risk of ischemic stroke: A systematic review and meta-analysis. J Arrhythm. 2019; 35(3):499-505. PMC: 6595320. DOI: 10.1002/joa3.12187. View

18.

Sacco R, Kasner S, Broderick J, Caplan L, Connors J, Culebras A . An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7):2064-89. PMC: 11078537. DOI: 10.1161/STR.0b013e318296aeca. View

19.

Glotzer T, Hellkamp A, Zimmerman J, Sweeney M, Yee R, Marinchak R . Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003; 107(12):1614-9. DOI: 10.1161/01.CIR.0000057981.70380.45. View

20.

Aronow W, Ahn C, Mercando A, Epstein S, Gutstein H . Correlation of paroxysmal supraventricular tachycardia, atrial fibrillation, and sinus rhythm with incidences of new thromboembolic stroke in 1476 old-old patients. Aging (Milano). 1996; 8(1):32-4. DOI: 10.1007/BF03340112. View